
From Dealmaking to Strategic Access: The New Partnership Agenda in Life Sciences
In the rapidly evolving life sciences sector, traditional transactional dealmaking is no longer sufficient to secure a competitive edge. “From Dealmaking to Strategic Access: The New Partnership Agenda in Life Sciences” explores a critical paradigm shift: biopharma organizations are moving beyond isolated mergers, acquisitions, and vendor transactions. Instead, today’s market demands long-term, integrated partnerships focused on global launch excellence, operational sustainability, and real-world value realization. By shifting the objective from mere transactional volume to continuous strategic access—sharing both risks and technical capabilities—organizations can effectively accelerate development pipelines, mitigate operational vulnerabilities, and ultimately deliver life-improving therapies to patients much faster.







